financetom
Business
financetom
/
Business
/
2023 Deal Street Outlook: Street cautiously optimistic on mergers and acquisitions, sees boost in infra funding
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
2023 Deal Street Outlook: Street cautiously optimistic on mergers and acquisitions, sees boost in infra funding
Dec 1, 2022 8:44 AM

As 2022 comes to end, the latest episode of Big Deal focuses on the year that was for deal street, the key highlights, , and then also crystal gazes into what's coming and picking up on the key trends for next year.

Share Market Live

NSE

Manisha Girotra, CEO, Moelis India, and Zia Mody, Founding Partner at AZB & Partners, delve deep into deal trends and give their perspective.

Mody said, “Certainly the situation with Russia and Ukraine and the whole disaffection — if you like — with China, has had only one beneficiary in that sense, which is India. So I think that the deal outlook, if you like, for the next year, it won't be bad, but it will be slow and steady. I think what will make it a bit slow is the valuation reset it is happening, but it’s happening slower than we as intermediaries would like to do deals.”

Girotra said, “India stood out in terms of growth compared to the other countries, and also we are benefiting enormously from the structural reforms that we took undertook in the last 10 years, and the reforms that we are promising to take undertake in the next 10 years."

Girotra said she is cautiously optimistic and that she strongly believes that India will attract a lot of capital, just because of what it has done in the past. "I believe that capital will not just come into the few sectors that it used to come into play the Indian demographics, but in a wider set of sectors as people are getting more comfortable on India as a as an economy and the Indian government and its seriousness to reforms.”

Watch video for more.

Also Read: Big Deal | Trends emerging in startup space, says Gaja Capital

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved